Julie Milojevic

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Thomas Dörner, Maximilian Posch, Yue Li et al. · Annals of the Rheumatic Diseases · 2019 · 200 citations

Life Sciences, Immunology, Pharmacology +17

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng et al. · The Lancet Rheumatology · 2020 · 126 citations

Life Sciences, Clinical Sciences, Immunology +14

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Hong Zhang, Dana V. Rizk, Vlado Perkovic et al. · Kidney International · 2023 · 121 citations · Full text

Medicine, Nephrology, Pharmacology +17

Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial

Antonio M. Risitano, Alexander Röth, Juliette Soret et al. · The Lancet Haematology · 2021 · 106 citations

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

Edwin Wong, Carla Nester, Teresa Cavero et al. · Kidney International Reports · 2023 · 97 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17